search
Back to results

Safety Study of Using Stem Cells to Stimulate Development of New Blood Vessels in Peripheral Vascular Disease

Primary Purpose

Peripheral Vascular Diseases

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
adult stem cells
Sponsored by
Murphy, Michael P., MD
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Vascular Diseases

Eligibility Criteria

21 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Severe peripheral vascular disease not amenable to bypass or angioplasty Age >21 years old Normal renal function (creatinine < 1.6) Exclusion Criteria: Congestive heart failure (ejection fraction [EF]<30%) History of cancer or myeloproliferative disorders Proliferative retinopathy Pregnancy Cognitively disabled

Sites / Locations

  • Indiana University School of MedicineRecruiting

Outcomes

Primary Outcome Measures

Adverse events recorded in the 12 week study period
Serious Adverse events recorded for one year

Secondary Outcome Measures

Changes in limb perfusion after treatment with stem cells will be assessed with arteriography, blood pressure recordings, oxygen measurements, and wound healing

Full Information

First Posted
June 6, 2005
Last Updated
June 23, 2005
Sponsor
Murphy, Michael P., MD
Collaborators
Indiana University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT00113243
Brief Title
Safety Study of Using Stem Cells to Stimulate Development of New Blood Vessels in Peripheral Vascular Disease
Official Title
Phase I Study of Stem Cell Mediated Angiogenesis for Limb Threatening Ischemia
Study Type
Interventional

2. Study Status

Record Verification Date
June 2005
Overall Recruitment Status
Unknown status
Study Start Date
December 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2007 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Murphy, Michael P., MD
Collaborators
Indiana University School of Medicine

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine if bone marrow derived adult stem cells are safe and effective in inducing development of new blood vessels (angiogenesis) in the legs of patients with severe peripheral vascular disease.
Detailed Description
Presently there are no effective medical therapies to enhance blood flow in the legs of patients with peripheral vascular disease. For patients with limb threatening ischemia the only option for relief of rest pain or gangrene is amputation. There is evidence in animal and clinical studies that adult stem cells in the bone marrow, called endothelial progenitor cells, participate in the development of new blood vessels, a process called angiogenesis. In this investigation, patients with limb threatening ischemia will have their bone marrow harvested and the stem cells will then be removed and injected directly into the muscle of the diseased leg. The procedure will require about 4 hours and the subjects will be admitted to the Indiana University Medical Center overnight. The follow-up period is 12 weeks and the analysis will consist of examinations at 1, 2, 4, 6, 8, and 12 weeks. Adverse and serious adverse events will be recorded during this time period. Diagnostic studies will be obtained to measure blood flow in the treated leg during the follow up period and include transcutaneous (skin) oxygen measurements, pressure recordings in the leg, arteriography, magnetic resonance imaging, and wound healing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Vascular Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
adult stem cells
Primary Outcome Measure Information:
Title
Adverse events recorded in the 12 week study period
Title
Serious Adverse events recorded for one year
Secondary Outcome Measure Information:
Title
Changes in limb perfusion after treatment with stem cells will be assessed with arteriography, blood pressure recordings, oxygen measurements, and wound healing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Severe peripheral vascular disease not amenable to bypass or angioplasty Age >21 years old Normal renal function (creatinine < 1.6) Exclusion Criteria: Congestive heart failure (ejection fraction [EF]<30%) History of cancer or myeloproliferative disorders Proliferative retinopathy Pregnancy Cognitively disabled
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael P Murphy, MD
Phone
(317) 630-8288
Email
mipmurph@iupui.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Julie Lacy, RN
Phone
(317)962-0138
Email
julacy@iupui.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael P Murphy, MD
Organizational Affiliation
Indiana University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Indiana University School of Medicine
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael P Murphy, MD
Phone
317-630-8288
Email
mipmurph@iupui.edu
First Name & Middle Initial & Last Name & Degree
Janet Klein, RN
Phone
(317) 962-0287
Email
jswklein@iupui.edu
First Name & Middle Initial & Last Name & Degree
Keith L March, MD,PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
15193699
Citation
Rehman J, Li J, Parvathaneni L, Karlsson G, Panchal VR, Temm CJ, Mahenthiran J, March KL. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. J Am Coll Cardiol. 2004 Jun 16;43(12):2314-8. doi: 10.1016/j.jacc.2004.02.049.
Results Reference
background
PubMed Identifier
15277189
Citation
March KL, Johnstone BH. Cellular approaches to tissue repair in cardiovascular disease: the more we know, the more there is to learn. Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H458-63. doi: 10.1152/ajpheart.00343.2004. No abstract available.
Results Reference
background
PubMed Identifier
12615796
Citation
Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003 Mar 4;107(8):1164-9. doi: 10.1161/01.cir.0000058702.69484.a0.
Results Reference
background
PubMed Identifier
27021379
Citation
Liang TW, Jester A, Motaganahalli RL, Wilson MG, G'Sell P, Akingba GA, Fajardo A, Murphy MP. Autologous bone marrow mononuclear cell therapy for critical limb ischemia is effective and durable. J Vasc Surg. 2016 Jun;63(6):1541-5. doi: 10.1016/j.jvs.2016.01.022. Epub 2016 Mar 23.
Results Reference
derived
Links:
URL
http://www.gcrc.iupui.edu/
Description
General Clinical Research Center at Indiana University School of Medicine

Learn more about this trial

Safety Study of Using Stem Cells to Stimulate Development of New Blood Vessels in Peripheral Vascular Disease

We'll reach out to this number within 24 hrs